Nakashima T, Maehara Y, Kohnoe S, Hayashi I, Katsuta Y
Department of Otolaryngology, National Kyushu Cancer Center, Fukuoka, Japan.
Head Neck. 1990 Sep-Oct;12(5):406-10. doi: 10.1002/hed.2880120506.
The chemosensitivities of 42 human head and neck squamous cell carcinomas were examined using the in vitro succinate dehydrogenase inhibition (SDI) test. The tumor tissues obtained at surgery or biopsy were exposed to five different antitumor drugs: adriamycin (ADM), cisplatin (CDDP), carboquone (CQ), 5-fluorouracil (5-FU), and 1-hexylcarbamoyl-5-fluorouracil (HCFU). The results were analyzed according to the histopathologic degree of differentiation of well, moderately, and poorly differentiated squamous cell carcinoma. The average decrease in succinate dehydrogenase activity was 43.2 +/- 24.9 for ADM, 29.0 +/- 14.2 for CDDP, 32.9 +/- 17.6 for CQ, 64.2 +/- 20.6 for 5-FU, and 26.8 +/- 16.9 for HCFU. There was a statistically significant difference in the decrease of succinate dehydrogenase activity between well and poorly differentiated squamous cell carcinomas. These data suggest that, for patients with a poorly differentiated squamous cell carcinoma, the response to anti-cancer drugs may be more satisfactory than in those with a well-differentiated squamous cell carcinoma.
采用体外琥珀酸脱氢酶抑制（SDI）试验检测了42例人头颈部鳞状细胞癌的化疗敏感性。将手术或活检获取的肿瘤组织暴露于五种不同的抗肿瘤药物：阿霉素（ADM）、顺铂（CDDP）、卡波醌（CQ）、5-氟尿嘧啶（5-FU）和1-己基氨基甲酰-5-氟尿嘧啶（HCFU）。根据高分化、中分化和低分化鳞状细胞癌的组织病理学分化程度对结果进行分析。阿霉素导致琥珀酸脱氢酶活性平均下降43.2±24.9，顺铂为29.0±14.2，卡波醌为32.9±17.6，5-氟尿嘧啶为64.2±20.6，1-己基氨基甲酰-5-氟尿嘧啶为26.8±16.9。高分化和低分化鳞状细胞癌之间琥珀酸脱氢酶活性下降存在统计学显著差异。这些数据表明，对于低分化鳞状细胞癌患者，其对抗癌药物的反应可能比高分化鳞状细胞癌患者更令人满意。
